EUCTR2006-006462-42-GB进行中（未招募）1 期
A PHASE IV, OPEN LABEL, PILOT STUDY OF THE TREATMENT OF CHILDREN WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) USING LOCOBASE REPAIR® AS AN ADJUNCTIVE TO STANDARD TREATMENT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Has given written informed consent (parents or guardian, child if applicable)
- •2.At least 18 months and less than 16 years old at study entry
- •3.Moderate to severe AD
- •4.Continuous use of topical corticosteroid or topical calcineurin inhibitor (TCI) as active treatment of AD for more than 4 weeks prior to day 1
- •5.In the opinion of the investigator, subjects are unlikely to require a significant change to their current treatment regimen during the study period
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Has infected lesions
- •2.The last assessment of any clinical study within 3 months prior to the expected date of entering into the study
- •3.Subject is currently using systemic corticosteroids
- •4.Current use of Locobase REPAIR®
- •5.Known allergy to Locobase REPAIR® or any of its components
- •6.Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the study
研究者
相似试验
进行中（未招募）
1 期
DREAM studyEUCTR2016-004646-29-ESFundación SEIMC-GESIDA64
进行中（未招募）
1 期
Post-marketing study of safety and efficacy of GARDASIL in young Japanese women.Human Papillomavirus infectionEUCTR2015-002932-42-Outside-EU/EEAMSD K.K., a subsidiary of Merck & Co., Inc1,000
已完成
4 期
Open label clinical trial to evaluate safety and tolerability of FDC of Ebastine (10 mg) and Phenylephrine (10 mg)CTRI/2018/08/015262Sterling Lab145
进行中（未招募）
1 期
A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients with Severe Keratitis who have not improved despite regular use of tear substitutes before and after Exposure to an Adverse Controlled EnvironmentEUCTR2019-000982-19-ESInstituto de Oftalmobiología Aplicada (IOBA)25
进行中（未招募）
不适用
An open-label, phase IV, pilot study, to evaluate confocal microscopic findings of cornea, ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switching from latanoprost 0.005% (preserved) to preservative free tafluprost 0.0015% eye drops.EUCTR2010-021039-14-FITampere University, Faculty of Medicine, Department of Ophthalmology30